Table 2 Outcomes and characteristics of the treatments of group A (150 < P/F ≤ 200) vs. group B (100 < P/F ≤ 150) and group A + B (moderate ARDS, 100 < P/F ≤ 200) vs. group C (severe ARDS, P/F ≤ 100)
Outcomes and treatments | Group A (n = 29) | Group B (n = 68) | Group A + B (Moderate ARDS) (n = 97) | Group C (Severe ARDS) (n = 31) | p | ||
|---|---|---|---|---|---|---|---|
A vs. B | B vs. C | A + B vs. C | |||||
Outcomes | |||||||
Mortality, n (%) | 4 (13.8) | 9 (13.2) | 13 (13.4) | 9 (29.0) | 1 | 0.059 | 0.044 |
OTI, n (%) | 2 (6.9) | 8 (11.8) | 10 (10.3) | 4 (12.9) | 0.72 | 1 | 0.69 |
Days of hospitalization, median [IQR] | 13 [10–17] | 15 [12–19] | 14 [12–19] | 15 [12–19] | 0.25 | 0.08 | 0.038 |
CPAP: PEEP max, median [IQR], mmHg | 7 [7–7.8] | 8 [7–8.25] | 7.5 [7.8] | 7.5 [7.8] | 0.12 | 0.41 | 0.25 |
PSV: PEEP max. median [IQR], mmHg | 10 [6–10] | 8 [5–8] | 8 [5.25–8] | 8 [6–8.25] | 0.23 | 0.29 | 0.46 |
PSV: PS max, median [IQR], mmHg | 5.5 [4.75–6] | 6 [4–8] | 6 [4–8] | 5 [4.5–7.5] | 0.59 | 0.79 | 0.87 |
Continuous ventilation (≥ 18 h/day), n (%) | 7 (24.1) | 15 (22.1) | 22 (22.7) | 17 (54.8) | 0.82 | 0.002 | 0.0007 |
Overall days of ventilation, median [IQR] | 5 [3–9] | 6 [4–9] | 6 [4–9] | 6 [4–9] | 0.94 | 0.79 | 0.86 |
Days from start NRS to OTI, median [IQR] | 10.5 [NA] | 7 [3–12] | 7 [4–13] | 4.5 [4–8.75] | 0.50 | 0.648 | 0.41 |
Days from start NRS to weaning, median [IQR] | 5 [3–11] | 6 [4–9] | 6 [4–9] | 6.5 [4–9.25] | 0.543 | 0.533 | 0.375 |
Conversion rate to NIV, n (%) | 5 (17.2) | 13 (19.1) | 18 (18.6) | 15 (48.4) | 0.83 | 0.002 | 0.003 |
Tocilizumab, n (%) | 3 (10.3) | 10 (14.7) | 13 (13.4) | 4 (12.9) | 0.75 | 1 | 0.94 |
Remdesivir, n (%) | 12 (41.4) | 20 (29.4) | 32 (33.0) | 3 (9.7) | 0.25 | 0.041 | 0.011 |
Steroids, n (%) | 29 (100) | 68 (100) | 97 (100) | 31 (100) | 1 | 1 | 1 |
Heparin, n (%) | 29 (100) | 68 (100) | 97 (100) | 31 (100) | 1 | 1 | 1 |